DK3886858T3 - Forbindelser til behandling af øjensygdomme forbundet med for megen vaskularisering - Google Patents

Forbindelser til behandling af øjensygdomme forbundet med for megen vaskularisering Download PDF

Info

Publication number
DK3886858T3
DK3886858T3 DK20838435.4T DK20838435T DK3886858T3 DK 3886858 T3 DK3886858 T3 DK 3886858T3 DK 20838435 T DK20838435 T DK 20838435T DK 3886858 T3 DK3886858 T3 DK 3886858T3
Authority
DK
Denmark
Prior art keywords
compounds
treatment
diseases associated
eye diseases
excessive vascularization
Prior art date
Application number
DK20838435.4T
Other languages
Danish (da)
English (en)
Inventor
Helena Eriksson
Joel Kaye
Marie Törngren
Original Assignee
Active Biotech Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Active Biotech Ab filed Critical Active Biotech Ab
Application granted granted Critical
Publication of DK3886858T3 publication Critical patent/DK3886858T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/47042-Quinolinones, e.g. carbostyril
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503Immunoglobulin superfamily
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/30Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/32Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK20838435.4T 2019-12-19 2020-12-18 Forbindelser til behandling af øjensygdomme forbundet med for megen vaskularisering DK3886858T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19218062 2019-12-19
EP20156158 2020-02-07
PCT/EP2020/086993 WO2021123142A1 (en) 2019-12-19 2020-12-18 Compounds for treatment of eye diseases associated with excessive vascularisation

Publications (1)

Publication Number Publication Date
DK3886858T3 true DK3886858T3 (da) 2022-08-22

Family

ID=74141502

Family Applications (1)

Application Number Title Priority Date Filing Date
DK20838435.4T DK3886858T3 (da) 2019-12-19 2020-12-18 Forbindelser til behandling af øjensygdomme forbundet med for megen vaskularisering

Country Status (15)

Country Link
US (2) US11478465B2 (https=)
EP (2) EP3886858B1 (https=)
JP (1) JP7730816B2 (https=)
KR (1) KR20220118419A (https=)
CN (1) CN114845718B (https=)
AU (1) AU2020408179B2 (https=)
BR (1) BR112022009192A2 (https=)
CA (1) CA3157394A1 (https=)
DK (1) DK3886858T3 (https=)
ES (1) ES2921360T3 (https=)
IL (1) IL293469B2 (https=)
MX (1) MX2022006439A (https=)
PL (1) PL3886858T3 (https=)
WO (1) WO2021123142A1 (https=)
ZA (1) ZA202204939B (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3886946A1 (en) 2019-06-05 2021-10-06 Regeneron Pharmaceuticals, Inc. Devices and methods for precision dose delivery
KR20220118419A (ko) * 2019-12-19 2022-08-25 액티브 바이오테크 에이비 과도한 혈관신생과 관련된 안구 질병의 치료를 위한 화합물
PL4312986T3 (pl) 2021-04-01 2025-02-17 Active Biotech Ab Preparat lakwinimodu do stosowania do oczu
USD1120314S1 (en) 2022-11-30 2026-03-24 Regeneron Pharmaceuticals, Inc. Dose delivery device
AU2024306742A1 (en) * 2023-06-28 2025-12-04 Active Biotech Ab Quinoline carboxamides for use in the treatment of mpn
CN117256554A (zh) * 2023-09-08 2023-12-22 益诺思生物技术南通有限公司 一种c57bl/6j小鼠新生血管型眼病模型及其构建方法
KR102925647B1 (ko) * 2023-10-13 2026-02-11 재단법인 대구경북첨단의료산업진흥재단 안질환 치료제

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6077851A (en) 1998-04-27 2000-06-20 Active Biotech Ab Quinoline derivatives
SE9801474D0 (sv) 1998-04-27 1998-04-27 Active Biotech Ab Quinoline Derivatives
US6875869B2 (en) 2002-06-12 2005-04-05 Active Biotech Ab Process for the manufacture of quinoline derivatives
US9265725B2 (en) 2002-10-25 2016-02-23 Foamix Pharmaceuticals Ltd. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
WO2008124828A1 (en) * 2007-04-10 2008-10-16 Myriad Genetics, Inc. Methods for treating vascular disruption disorders
WO2010070449A2 (en) 2008-12-17 2010-06-24 Actavis Group Ptc Ehf Highly pure laquinimod or a pharmaceutically acceptable salt thereof
WO2012006538A1 (en) * 2010-07-09 2012-01-12 Teva Pharmaceutical Industries Ltd. Deuterated n-ethyl-n-phenyl-1,2-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide, salts and uses thereof
EP2463289A1 (en) 2010-11-26 2012-06-13 Almirall, S.A. Imidazo[1,2-b]pyridazine derivatives as JAK inhibitors
EP2527344A1 (en) 2011-05-25 2012-11-28 Almirall, S.A. Pyridin-2(1H)-one derivatives useful as medicaments for the treatment of myeloproliferative disorders, transplant rejection, immune-mediated and inflammatory diseases
EP2537517A1 (en) * 2011-06-22 2012-12-26 Active Biotech AB Deuterium-enriched 4-hydroxy-5-methoxy-n,1-dimethyl-2-oxo-n-[(4-trifluoro-methyl)phenyl]-1,2-dihydroquinoline-3-carboxamide
IN2014MN00333A (https=) 2011-07-28 2015-09-25 Teva Pharma
US20150111833A1 (en) * 2012-04-20 2015-04-23 Howard University Method Of Treating An Ocular Disease And Compositions Effective For Treating An Ocular Disease
EP2849762A4 (en) 2012-05-16 2016-02-24 Aadigen Llc MULTI-TARGET MODULATION FOR TREATING FIBROSIS AND INFLAMMATORY DISORDERS
TW201400117A (zh) 2012-06-05 2014-01-01 Teva Pharma 使用拉喹莫德治療眼發炎疾病
MX373894B (es) * 2012-11-08 2020-07-09 Clearside Biomedical Inc Métodos y dispositivos para el tratamiento de trastornos oculares en sujetos humanos.
CN109432073A (zh) 2013-01-08 2019-03-08 帕萨罗杰卡有限公司 Mgbg在制备治疗或预防进行性ms及其进展的药物中的用途
EP3019526A1 (en) * 2013-07-11 2016-05-18 Novartis AG Use of a vegf antagonist in treating chorioretinal neovascular and permeability disorders in paediatric patients
WO2015060812A1 (en) 2013-10-21 2015-04-30 Howard University Treating ocular disease with efflux transporter inhibitors
EP3068395A4 (en) 2013-11-15 2017-07-12 Teva Pharmaceutical Industries Ltd. Treatment of glaucoma using laquinimod
CA2933900A1 (en) * 2013-12-20 2015-06-25 Georgia Tech Research Corporation Formulations and methods for targeted ocular delivery of therapeutic agents
WO2017120355A1 (en) 2016-01-06 2017-07-13 Teva Pharmaceutical Industries Ltd. Dihydroquinolines and uses thereof
CA3010862A1 (en) 2016-01-08 2017-07-13 Clearside Biomedical, Inc. Methods and devices for treating posterior ocular disorderswith aflibercept and other biologics
JP2020528082A (ja) * 2017-07-17 2020-09-17 ロイズマン,キース 加齢黄斑変性と他の眼疾患の治療用の細胞透過性ペプチドを使用する治療薬の局所送達
MX2020006460A (es) 2017-12-22 2020-11-06 Chemocentryx Inc Compuestos de anillo 5,5 fusionado sustituido con diarilo como inhibidores de c5ar.
WO2019126424A1 (en) 2017-12-22 2019-06-27 Chemocentryx, Inc. DIARYL SUBSTITUTED 6,5-FUSED RING COMPOUNDS AS C5aR INHIBITORS
BR112020019822A2 (pt) 2018-04-02 2021-03-16 Chemocentryx, Inc. Profármacos de antagonistas bicíclicos fundidos de c5ar
KR20220118419A (ko) * 2019-12-19 2022-08-25 액티브 바이오테크 에이비 과도한 혈관신생과 관련된 안구 질병의 치료를 위한 화합물

Also Published As

Publication number Publication date
PL3886858T3 (pl) 2022-08-29
EP3886858B1 (en) 2022-05-11
ZA202204939B (en) 2023-12-20
US12208091B2 (en) 2025-01-28
EP4094765A1 (en) 2022-11-30
ES2921360T3 (es) 2022-08-24
CN114845718A (zh) 2022-08-02
KR20220118419A (ko) 2022-08-25
IL293469A (en) 2022-08-01
CN114845718B (zh) 2025-05-16
CA3157394A1 (en) 2021-06-24
MX2022006439A (es) 2022-07-19
WO2021123142A1 (en) 2021-06-24
BR112022009192A2 (pt) 2022-07-26
EP3886858A1 (en) 2021-10-06
US20230066364A1 (en) 2023-03-02
US20210322400A1 (en) 2021-10-21
AU2020408179A1 (en) 2022-06-30
JP7730816B2 (ja) 2025-08-28
IL293469B1 (en) 2023-12-01
JP2023509336A (ja) 2023-03-08
US11478465B2 (en) 2022-10-25
AU2020408179B2 (en) 2025-04-10
IL293469B2 (en) 2024-04-01

Similar Documents

Publication Publication Date Title
DK3886858T3 (da) Forbindelser til behandling af øjensygdomme forbundet med for megen vaskularisering
DK3743070T3 (da) Forbindelser til behandling af kinaseafhængige lidelser
IL281773A (en) Ophthalmic composition for treatment of dry eye disease
DK3728271T3 (da) Makrocykliske forbindelser til behandling af sygdomme
IL271046A (en) Compounds for treating huntington's disease
DK3681500T3 (da) Anvendelse af pilocarpinhydrochlorid til behandling af presbyopi
DK3668509T3 (da) Fremgangsmåde til behandling af amyotrofisk lateralsklerose med pridopidin
DK3399962T3 (da) Oftalmisk sammensætning til behandling af tør øjensygdom
DK3240538T3 (da) Anvendelse af masitinib til behandling af en underpopulation af patienter med amyotrofisk lateralsklerose
DK3865484T3 (da) Pde9-hæmmer med imidazopyrazinon-rygrad til behandling af perifere sygdomme
DK3498278T3 (da) Forbindelser til behandling af sygdomme relateret til DUX4-ekspression
IL286340A (en) Topical formulations for treatment of peripheral neuropathies
DK3548061T3 (da) Behandling af neurologiske sygdomme
IL281244A (en) Combination therapy for the treatment of liver disease
DK3097085T3 (da) Benzoxazinonderivater til behandling af hudsygdomme
DK3773558T3 (da) Kombinationsbehandling af artritisk sygdom
IL282330A (en) Therapeutic compounds
DK3612208T5 (da) Coversin til behandlingen af autoimmune sygdomme med blisterdannelse
DK3210973T3 (da) Heteroarylforbindelser til behandling af oftalmiske sygdomme
DK3439661T3 (da) Fremgangsmåder til behandling af øjenlidelser
DK3578562T3 (da) L-valinatamidbenzoxaborolderivater til behandling af parasitiske sygdomme
DK3833746T5 (da) Mini-gde til behandlingen af glykogenlagringssygdom iii
IL282700A (en) Heterocyclic compounds for the treatment of epilepsy
DK3373931T3 (da) Heterocykliske forbindelser til behandling af sygdom
DK3897595T3 (da) Nutraceutisk ophthalmisk sammensætning til behandlingen af retinale pathologier med en neovaskulær komponent